Author: Darwish, Ilyse; Miller, Chris; Kain, Kevin C.; Liles, W. Conrad
Title: Inhaled Nitric Oxide Therapy Fails to Improve Outcome in Experimental Severe Influenza Document date: 2012_1_13
ID: 1rktb6yq_1
Snippet: Influenza A viruses infect approximately 5-15% of the population, resulting in 250-500 thousands deaths each year (1) . The most widely used class of drugs for treatment of clinical influenza is the neuraminidase inhibitors, including oseltamivir and zanamivir. The clinical impact of these drugs is limited by the development of antiviral drug resistance. Specifically, decreased efficacy of neuraminidase inhibitors has been reported against season.....
Document: Influenza A viruses infect approximately 5-15% of the population, resulting in 250-500 thousands deaths each year (1) . The most widely used class of drugs for treatment of clinical influenza is the neuraminidase inhibitors, including oseltamivir and zanamivir. The clinical impact of these drugs is limited by the development of antiviral drug resistance. Specifically, decreased efficacy of neuraminidase inhibitors has been reported against seasonal H1N1 influenza and 2009 novel swine-origin H1N1 influenza, as well as avian influenza H5N1 virus (2) (3) (4) (5) (6) (7) (8) (9) . In addition, initiation of antiviral therapy in influenza A virus-infected individuals beyond the first 48-72 hours after the onset of influenza symptoms is asso-ciated with greater mortality and decreased antiviral efficacy compared with treatment initiated within 48-72 hours of symptom onset (10) (11) (12) (13) (14) (15) . These caveats underscore the need to develop novel and effective influenza therapeutic strategies. Further investigation of other intervention strategies which have shown promising results against influenza A viruses in vitro but have not been investigated in vivo are warranted.
Search related documents:
Co phrase search for related documents- antiviral therapy and clinical influenza: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral therapy and clinical influenza treatment: 1
- antiviral therapy and drug resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- antiviral therapy and H1N1 influenza: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- antiviral therapy and influenza symptom: 1
- antiviral therapy and Influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral therapy and influenza vitro virus: 1, 2
- antiviral therapy and intervention strategy: 1
- antiviral therapy and neuraminidase inhibitor: 1, 2, 3, 4, 5, 6
- antiviral therapy and novel swine origin H1N1 influenza: 1, 2
- antiviral therapy and seasonal H1N1 influenza: 1, 2, 3
- antiviral therapy and swine origin: 1, 2, 3, 4
- antiviral therapy and swine origin H1N1 influenza: 1, 2, 3
- antiviral therapy and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- antiviral therapy and therapeutic strategy: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral therapy and virus infect: 1, 2
- antiviral therapy and vitro virus: 1, 2, 3, 4, 5, 6
- antiviral therapy and zanamivir oseltamivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antiviral therapy and zanamivir oseltamivir include: 1
Co phrase search for related documents, hyperlinks ordered by date